Royalty Pharma $RPRX Dark Pool Trades Detected

  • Post category:Dark Pool Stocks
  • Reading time:6 mins read
Get Email Alerts and Follow Us:

Dark pool trades occurred in Royalty Pharma $RPRX stock from October 25 – 28, 2002. The dark pool trading appears to be buying because of how $RPRX stock rose following the prints being made public.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. The compnay’s portfolio includes royalties on commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta and Vertex’s Kalydeco, Symdeko and Trikafta, and development-stage product candidates.

Dark Pool Trading in Royalty Pharma $RPRX Stock

Royalty Pharma stock chart on October 29, 2022, with dark pool trades in orange bars with a table to the right with the text TIME SYMBOL MESSAGE PRICE 10/28/22 RPRX 237,245 DARK BLOCK $10M 13.8% AvgVol $42.32 10/27/22 RPRX 349,200 DARK ISO $14M 20.32% AvgVol $42.25 10/26/22 RPRX 106,354 DARK BLOCK $4.4M 5.9% AvgVol $42.12 10/25/22 RPRX 132,458 DARK BLOCK $5.4M 7.41 % AvgVol $41.42 10/25/22 RPRX 503,500 DARK AVGPRC $20M 28.18% AvgVol $41.42

Royalty Pharma will announce third quarter 2022 financial results on November 8, 2022, before the U.S. financial markets open. Could the dark pool orders be institutional investors front-running the upcoming Q3 financial results?

Bullish Option Flow Occurred On October 24, 2022

Bullish option flow was detected in $RPRX stock on October 24, 2022. Open interest is rising in the $45 call option contract that expires on January 20, 2023, which favors the Bulls.

RPRX stock call option chart on October 29, 2022, showing rising open interest in the $45 January 20, 2023, call option contract.

Royalty Pharma Declares Fourth Quarter 2022 Dividend

On October 17, 2022, the board of directors of Royalty Pharma plc $RPRX approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on December 15, 2022, to shareholders of record at the close of business on November 18, 2022.

Royalty Pharma enters schizophrenia R&D funding collaboration with Merck

On October 12, 2022, Royalty Pharma $RPRX entered into an agreement with Merck (MRK) to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia. Royalty Pharma will provide $50 million upfront to Merck to support ongoing development of MK-8189. Following Merck’s decision to proceed with Phase 3, Royalty Pharma has the option to provide an additional $375 million to co-fund the pivotal clinical development program. Royalty Pharma will be eligible for milestone payments associated with certain regulatory approvals for MK-8189 as well as royalties on annual worldwide sales of any approved product.

Jim Cramer: Newly public Royalty Pharma is a great way to play biotech

Royalty Pharma $RPRX Stock Technical Analysis

Royalty Pharma $RPRX stock is in a technical uptrend. Long-term indicators suggest a continuation of the uptrend. Short-term indicators suggest the Royalty Pharma stock is approaching overbought territory, so profit taking or a trend reversal is possible. The stock has formed a downtrend channel breakout pattern on the chart.

Royalty Pharma stock chart on October 29, 2022, with a downtrend channel breakout and a positive MACD and positive money flow.
Get Email Alerts and Follow Us: